An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 30, 2024

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Bortezomib

Bortezomib 2 mg per week subcutaneously, for twelve weeks in total

Trial Locations (1)

Peking Union Medical Cllege Hospital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER